Best initial treatments for patients with Cardiovascular-Kidney-Metabolic Syndrome.
Optimal first line therapies for patients with Cardiovascular-Kidney-Metabolic (CKM) Syndrome.
This study is looking at the best first treatments for people with Cardiovascular-Kidney-Metabolic Syndrome and diabetes, comparing older options like metformin with newer medications to see which ones work better for keeping your heart and kidneys healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11046133 on NIH RePORTER |
What this research studies
This research investigates the most effective first-line therapies for patients suffering from Cardiovascular-Kidney-Metabolic (CKM) Syndrome, particularly focusing on those with diabetes. It aims to compare traditional treatments like metformin with newer medications such as glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) to determine their effectiveness in preventing cardiovascular disease and kidney complications. The study will utilize a national longitudinal approach, gathering data from patient reports, clinical records, and laboratory results to assess treatment outcomes over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 55 and older with new-onset diabetes and risk factors such as hypertension, obesity, and dyslipidemia.
Not a fit: Patients without diabetes or those who already have established cardiovascular disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that significantly reduce the risk of cardiovascular and kidney complications for patients with CKM Syndrome.
How similar studies have performed: Previous research has shown promising results with GLP1RA and SGLT2i in patients with pre-existing cardiovascular disease, but this specific comparison in high-risk, drug-naïve patients is relatively novel.
Where this research is happening
Nashville, United States
- Veterans Health Administration — Nashville, United States (Active)
Researchers
- Principal investigator: Roumie, Christianne L. — Veterans Health Administration
- Study coordinator: Roumie, Christianne L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.